Lacosamide Fresenius Kabi (Lacosamide)

Lacosamide works by selectively enhancing the slow inactivation of voltage‑gated sodium channels in neurons. This stabilizes the neuronal membrane, reduces hyperexcitability, and limits the spread of abnormal electrical activity that can trigger seizures.

The dosage of lacosamide is individualized and set by the prescribing clinician based on the patient’s condition, age, renal function, and response to therapy. Specific dosing regimens are not provided here and should be obtained from a qualified healthcare professional.

Safety data for lacosamide in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss risks and alternatives with the patient.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and import documentation.

Lacosamide has a unique mechanism that enhances slow sodium‑channel inactivation, differing from many other antiepileptics that block fast sodium channels or modulate GABA. This can provide an alternative option for patients who have inadequate response or intolerance to other agents.

Lacosamide intravenous solution should be stored at 2‑8 °C (refrigerated). Keep the product in its original container, protect it from light, and avoid freezing or shaking to maintain stability and potency.

Lacosamide is administered by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the prescriber and may be adjusted based on patient response and tolerability.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation or atrial fibrillation, severe skin reactions like Stevens‑Johnson syndrome, and rare cases of suicidal ideation. Patients should be monitored closely for these events, especially during treatment initiation.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with significant cardiac conduction disorders, severe renal impairment, or those taking interacting medications that may increase the risk of adverse effects.